Virendra K Jain
Certified Public Accountant
2 West 46th Street Suite 1014 New York, NY 10036
Tel: 718-874-6725
Email: vkjainusa@yahoo.com

PISGAH LABS INC., USA

AUDITED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

Virendra K Jain
Certified Public Accountant
2 West 46th Street Suite 1014 New York, NY 10036
Tel: 718-874-6725
Email: vkjainusa@yahoo.com

CONTENTS

Virendra K Jain
Certified Public Accountant
2 West 46th Street Suite 1014 New York, NY 10036
Tel: 718-874-6725
Email: vkjainusa@yahoo.com

Independent Accountant's Report

To,
The Shareholders of
Pisgah Laboratories Inc.
d/b/a - Pisgah Labs Inc.,
3222 Old Hendersonville Hwy,
Pisgah Forest, NC – 28768, USA

I have audited the accompanying financial statements of Pisgah Labs Inc., USA as of March 31, 2026, and 2025, and the related statements of Income, Retained earnings for the year then ended in accordance with standards established by the American Institute of Certified Public Accountants. These financial statements are the responsibility of the company's management. My responsibility is to express an opinion on these financial statements based on our audit.

I conducted my audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosure in the financial. An audit also includes assessing the accounting principles used and significant estimates made by the management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In my opinion, the financial statements referred to above present fairly, in all material respect, the financial position of Pisgah Labs Inc. USA as of March 31, 2026, and 2025, and the result of operations for the year ended March 31, 2026, and 2025, in conformity with accounting principles generally accepted in the United States of America.

For Virendra K Jain, CPA

VKJain 05/20/26

Virendra K Jain, CPA
New York, NY
License No. 093066
Date: May 20, 2026

PISGAH LABORATORIES INC. USA
BALANCE SHEET
MARCH 31, 2026 AND 2025

	As at March 31 2026 $	As at March 31 2025 $
Current Assets:		
Cash & Bank	1,739,347	261,338
Accounts Receivables	466,857	201,389
Unbilled Revenue	----	56,000
Other Receivables	3,210	3,607
Royalty Receivables	----	108,333
Inventory	895,599	874,965
Loans & Exchange	5,900	----
Prepaid Expenses	34,365	28,740
Total Current Assets	**3,145,278**	**1,534,372**
Fixed & Intangible Assets:		
Fixed Assets	4,298,281	4,208,221
Accumulated Depreciation	(1,816,244)	(1,680,979)
Net Fixed Assets	2,482,037	2,527,242
Intangible Assets	5,916,504	5,916,504
Accumulated Amortization & Impairment	(5,744,818)	(5,658,975)
Net Intangible Assets	171,686	257,529
Total Fixed & Intangible Assets	**2,653,723**	**2,784,771**
Other Assets:		
Capital – WIP (Note 5)	22,215,769	11,869,102
Deferred Taxes	52,529	105,058
Security Deposit	7,000	4,300
Total Other Assets	**22,275,298**	**11,978,460**
Total Assets	**28,074,299**	**16,297,603**

See accompanying notes to Financial Statements

PISGAH LABORATORIES INC. USA
BALANCE SHEET
MARCH 31, 2026 AND 2025

LIABILITIES AND STOCKHOLDERS EQUITY

	As at March 31 2026 $	As at March 31 2025 $
Current Liabilities:		
Accounts Payable	1,862,905	358,028
Accrued Expenses	208,683	177,118
Total Current Liabilities	**2,071,588**	**535,146**
Stockholders' Equity:		
Fair Value Adjustment Reserve	171,685	257,529
Common Stock (Note 3)	92,000	92,000
Redeemable Pref. Shares	41,950,000	27,250,000
Retaired Earnings	(16,210,974)	(11,837,072)
Total Stockholders' Equity	**26,002,711**	**15,762,457**
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	**28,074,299**	**16,297,603**

See accompanying notes to Financial Statements

PISGAH LABORATORIES INC. USA
STATEMENT OF INCOME
FOR THE YEAR ENDED MARCH 31, 2026 AND 2025

	2026	2025
	$	$
Revenue:		
Revenue from Operations	583,879	219,651
Other Income	529,332	550,467
Total Income	**1,113,211**	**770,118**
Expenses:		
Cost of Materials Consumed & Inventory Adjustment	207,069	153,725
Employee Benefit Expenses	2,894,066	3,172,846
Depreciation, Amortization & Impairment	221,109	220,047
Other Expenses	2,158,184	1,472,002
Total Operating Expenses	**5,480,428**	**5,018,620**
Income / (Loss) before Corporate Taxes	**(4,367,217)**	**(4,248,502)**
Deferred Taxes	52,529	52,529
Corporate Taxes (Note 4)	40,000	24,000
Net Income / (Loss)	**(4,459,746)**	**(4,325,031)**

See accompanying notes to Financial Statements

PISGAH LABORATORIES INC. USA
STATEMENT OF RETAINED EARNINGS
FOR THE YEAR ENDED MARCH 31, 2026 AND 2025

	2026 $	2025 $
Retained Earnings – Beginning of the Year	(11,837,072)	(16,988,391)
Fair Value Adjustment Reserve	85,844	9,476,350
Income / (Loss) for the year	(4,459,746)	(4,325,031)
Retained Earnings – End of the Year	**(16,210,974)**	**(11,837,072)**

See accompanying notes to Financial Statements

PISGAH LABORATORIES INC. USA
STATEMENT OF CASH FLOW
FOR THE YEAR ENDED MARCH 31, 2026 AND 2025

	2026	2025
Current Assets:	$	$
Cash flows from operating activities:		
Net Income (loss)	(4,459,746)	(4,235,031)
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	135,265	134,204
Amortization & impairment	85,844	85,843
Changes in assets and liabilities:		
Decrease / (Increase) in Accounts Receivables	(265,468)	(37,500)
Decrease / (Increase) in Unbilled Revenue	56,000	150,630
Decrease / (Increase) in Other Receivables	108,729	(111,940)
Decrease / (Increase) in Inventory	(20,634)	99,183
Decrease / (Increase) in Loans & Exchange	(5,900)	12,700
Decrease / (Increase) in Prepaid Expenses	(5,625)	4,135
Decrease / (Increase) in Accrued Expenses	31,566	25,360
Decrease / (Increase) in Accounts Payable	1,504,876	325,229
(Decrease) / Increase in Other Payables	-----	(46,000)
Total adjustments	**1,624,653**	**641,844**
Net cash provided by operating activities	**(2,835,093)**	**(3,683,187)**
Cash flow from investing activities:		
Decrease / (Increase) in Fixed Assets	(90,060)	(510,374)
Decrease / (Increase) in Capital WIP	(10,346,667)	(7,637,911)
Decrease / (Increase) in Other Assets	49,829	159,487
Net Cash from investing activities	**(10,386,898)**	**(7,988,798)**
Cash flow from financing activities:		
Increase in Investments	14,700,000	11,300,000
(Decrease) in Dividend Payable	----	----
Net Cash used from financing activities:	**14,700,000**	**11,300,000**
Net Increase / (Decrease) in cash	1,478,009	(371,985)
Cash at beginning of period	261,338	633,323
CASH AT END OF PERIOD	**1,739,347**	**261,338**

See accompanying notes to Financial Statements

PISGAH LABORATORIES INC. USA
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 2026 and 2025

Note 1 Organization:

Pisgah Laboratories Inc. (Pisgah) is C Corporation organized and incorporated under the laws of state of North Carolina (NC) founded in the year 1981. Pisgah is a contract manufacturer and developer of Active Pharmaceutical Ingredients (APIs) and Intermediates.

Note 2 Summary of Significant Accounting Policies:

Basis of Accounting:

The financial statements of the Company are prepared on the accrual basis of accounting and in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates in Financial Statements preparation:

The preparation of Financial statements in conformity with accounting principle generally accepted in United State of America require the use of estimates and assumptions that affect the reported amounts of assets & liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. The Company's financial statements include amounts that are based on management's best estimates and judgment Actual results could differ from those estimates.

Fixed Assets:

Acquisition of equipment, furniture and fixtures are capitalized in their respective accounts at cost. Ordinary maintenance and repair items are charged directly to expenses as incurred. The assets were revalued at the time of acquisition and fair market values were considered as carrying cost in the books.

Depreciation is being provided based in the estimated useful life using straight line method.

Revenue:

Revenue from sale of goods is recognized as net of returns when Company satisfies the performance obligation by transferring promised goods or services to customer. Revenue from services is recognized when all relevant activities are completed and the right to receive income is established.

PISGAH LABORATORIES INC. USA
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 2026 and 2025

Intangible Assets:

Intangible assets are stated at cost less accumulated amortization as at 03/31/2026 & 03/31/2025. However, impairment of $ 3,898,550 are included in accumulated amortization of $5,744,819 & $5,658,975 in 03/31/2026 & 03/31/2025. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition, and other economic factors (such as the stability of the industry, and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.

Inventories:

Items of inventories are valued lower of cost or estimated net realizable value.

Note 3 <u>**Shareholders Equity:**</u>

Pisgah Labs Inc have following Shareholding pattern as of March 31, 2026:

<u>**Authorized**</u>

Common Stock: 100,000 shares @ $ 1 per share:	Total $	100,000

<u>**Issued and Paid up**</u>

Common Stock: 92,000 shares @ $ 1 per share	Total $	92,000
Redeemable Preference shares 41,950 shares @ $ 1000	Total $	41,950,000
(Non-voting)	(Previous Year $ 27,250,000)	

Note 4 <u>**Corporate Tax:**</u>

Since the corporation has loss in the current year, Income tax provision not provided for Federal Corporate Tax. However, provision for NC State tax is included as per tax rates of the State of North Carolina.

PISGAH LABORATORIES INC. USA
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 2026 and 2025

Note 5 **Capital – Work in Progress:**

Company, setting up of the new manufacturing facility in United States, is in progress and management expects the same to be ready for its intended use by December'2026 and commercialization of its operations by September' 2027.

Note 6 **Related Party Disclosure:**

During the year Pisgah Labs Inc. issues Preference shares of USD 14,700,000 (Previous Year USD 11,300,000) to Ipca Pharmaceuticals Inc. USA.

During the year Pisgah Labs Inc. has purchased of its products from Ipca Laboratories Ltd., India for USD NIL (Previous Year USD 13,500).

During the year Pisgah Labs Inc. has sold one of its products to Unichem Pharmaceuticals (USA), Inc. for USD 72,800 (Previous Year USD 56,000).

Also, the company has outstanding receivables from Unichem Pharmaceuticals (USA), Inc. of USD NIL for sale of its products (Previous Year USD 56,000).

For Virendra K Jain, CPA

VKJain 05/20/2026

Virendra K Jain, CPA
License No. 093066
May 20, 2026